Thalidomide: Emerging role in cancer medicine

Annual Review of Medicine

Volumn 53, Issue , 2002, Pages 629-657

  Richardson, Paul ^a   Hideshima, Teru ^a   Anderson, Kenneth ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antiangiogenesis; Immunomodulation; Myeloma

Indexed keywords

ALCOHOL; ALLOPURINOL; ANTHRACYCLINE DERIVATIVE; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; BARBITURIC ACID DERIVATIVE; CENTRAL STIMULANT AGENT; CHLORPROMAZINE; CISPLATIN; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IMMUNOMODULATING AGENT; INTERLEUKIN 6; MELPHALAN; METHAMPHETAMINE; METHYLPHENIDATE; MITOXANTRONE; ORAL CONTRACEPTIVE AGENT; PENTOXIFYLLINE; PHOSPHODIESTERASE IV INHIBITOR; RESERPINE; SELECTIVE CYTOKINE INHIBITORY AGENT; STEROID; SULFONAMIDE; THALIDOMIDE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADSORPTION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; ERYTHEMA NODOSUM LEPROSUM; GASTROINTESTINAL TOXICITY; GLIOMA; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMODULATION; INFECTION; KAPOSI SARCOMA; KIDNEY CARCINOMA; MULTIPLE MYELOMA; NEUROTOXICITY; NONHUMAN; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SKIN DISEASE; SKIN MANIFESTATION; TERATOGENICITY; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ANGIOGENESIS INHIBITORS; ANIMALS; CLINICAL TRIALS; HUMANS; MULTIPLE MYELOMA; NEOPLASMS; PALLIATIVE CARE; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036182237     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.53.082901.104043     Document Type: Review

References (112)

1. The susceptible period for thalidomide malformations in man and monkey
2. Malformations caused by drugs in pregnancy
3. Thalidomide on the comeback trail
4. TM: A comprehensive program for controlling and monitoring access to thalidomide
5. Thalidomide and its impact in dermatology
6. Thalidomide is an inhibitor of angiogenesis
7. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization
8. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent
9. Anti-angiogenic treatment of metastatic melanoma, renal cell, ovarian and breast cancers with thalidomide: A phase II study
10. Randomized, phase II study of thalidomide in androgen-independent prostate cancer (AIPC)
11. A phase II trial of the anti-angiogenic agent, thalidomide, in patients with recurrent high-grade gliomas
12. Pilot trial of thalidomide postautologous peripheral blood progenitor cell transplantation (PBPC) in patients with metastatic breast cancer
13. A phase I/II trial of thalidomide as an antiangiogenic agent in the treatment of anvanced cancer
14. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade
15. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum
16. Thalidomide and the immune system. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells
17. Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in the peripheral blood
18. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
19. Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses
20. Thalidomide: From tragedy to new drug discovery
21. Chiral inversion and hydrolysis of thalidomide: Mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites
22. Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide
23. Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers
24. Pharmacokinetics of thalidomide in an elderly prostate cancer population
25. Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients
26. Thalidomide does not alter estrogen-progesterone hormone single dose pharmacokinetics
27. The pharmacology of thalidomide
28. The metabolic fate of thalidomide
29. Single-dose oral pharmacokinetics of three formulations of thalidomide in healthy male volunteers
30. Thalidomide in rabbit semen
31. The metabolism of thalidomide: The spontaneous hydrolysis of thalidomide in solution
32. The metabolism of thalidomide: Some biological effects of thalidomide and its metabolites
33. Effects of oral thalidomide on rat liver and skin microsomal P450 isozyme activities and on urinary porphyrin excretion: Interaction with oral hexachlorobenzene
34. Induction of drug metabolism in the rat by taglutimide, a sedative-hypnotic glutarimide derivative
35. Pharmacological properties of thalidomide (α-phthalimido glutarimide), a new sedative hypnotic drug
36. Anti-angiogenic therapy of human esophageal cancers with thalidomide in nude mice
37. Thalidomide in the treatment of erythema nodosum leprosum: With a note on selected laboratory abnormalities in erythema nodosum leprosum
38. Effects of thalidomide on neutrophil respiratory burst, chemotaxis, and transmigration of cytokineand endotoxin-activated endothelium
39. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation
40. Thalidomide in dermatology. New indications for an old drug
41. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes
42. Binding of thalidomide to 1-acid glycoprotein may be involved in its inhibition of TNF production
43. Does thalidomide affect IL-2 response and production?
44. Immunosuppressive properties of thalidomide. Inhibition of in vitro lymphocyte proliferation alone and in combination with cyclospofine or FK506
45. Thalidomide - Effect on T cell subsets as a possible mechanism of action
46. The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus
47. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures
48. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset
49. Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells
50. Inhibition of IL-12 production by thalidomide
51. Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with Concanavalin-A, Staphylococcal enterotoxin A, and purified protein derivative
52. Thalidomide with dexamethasone for resistant multiple myeloma
53. Deep venous thrombosis and thalidomide therapy for multiple myeloma
54. The saga of thalidomide (concluded): Neuropathy to embryopathy, with case reports of congenital anomalies
55. Thalidomide-induced peripheral neuropathy. Effect of serum factor on nerve cultures
56. Thalidomide neurotoxicity
57. Thalidomide neuropathy: A clinical, electrophysiological, and histological follow-up study
58. Marked anti-tumor effect from antiangiogenesis (AA) therapy with thalidomide (T) in high risk refractory multiple myeloma (MM)
59. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion
60. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B
61. Multiple myeloma: Increasing evidence for a multistep transformation process
62. Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines
63. The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: Therapeutic applications
64. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha
65. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: Therapeutic applications
66. Vascular endothelial growth factor (VEGF) triggers signaling cascades mediating multiple myeloma cell growth and migration
67. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma
68. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies
69. Antitumor activity of thalidomide in refractory multiple myeloma
70. WAF1,CIP1 in human brain tumors
71. Genetic determinants of p53-induced apoptosis and growth arrest
72. Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-gamma in multiple myeloma cells
73. Cytochrome c-dependent and -independent induction of apoptosis in multiple myeloma cells
74. Inhibition of NF-κB activity by thalidomide through suppression of IκB kinase activity
75. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
76. Thalidomide and its immunomodulatory drug inhibit multiple myeloma cell growth and angionenesis in vivo
77. Management of multiple myeloma today
78. Introduction to immunotherapy for multiple myeloma - Insights and advances
79. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia
80. Bone marrow angiogenesis and progression in multiple myeloma
81. Continuous low dose thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer
82. Angiogenesis in newly diagnosed multiple myeloma: Poor prognosis with increased microvessel density (MVD) in bone marrow biopsies
83. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma
84. Thalidomide and chemotherapy combination: Preliminary results of preclinical studies
85. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma
86. Thalidomide for resistant and relapsing myeloma
87. Thalidomide in the treatment of relapsed multiple myeloma
88. Thalidomide treatment of resistant or relapsed multiple myeloma patients
89. Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation
90. Single course D.T. PACE antiangiochemotherapy effects CR in plasma cell leukemia and fulminant multiple myeloma (MM)
91. Non-myeloppressive therapy with BLT-DC (Biaxin, low-dose thalidomide and dexamethasone) is highly active in Waldenstrom's macroglobunemia and myeloma
92. A phase I study of the safety and efficacy of CC5013 treatment for patients with relapsed multiple myeloma: Preliminary results
93. Thalidomide: Treatment of choice for aphthous ulcers in patients seropositive for human immunodeficiency virus
94. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection
95. Thalidomide in GVHD - Is anti-GVHD effect separable from antiangiogenesis?
96. Thalidomide for the treatment of graft-versus-host disease
97. Induction of morphological differentiation in the human leukemic cell line K562 by exposure to thalidomide metabolites
98. Thalidomide in acute myelogenous leukemia, myelodysplastic syndromes and myeloproliferative disorders
99. Angiogenesis in cancer, vascular, rheumatoid and other disease
100. Clinical applications of research on angiogenesis
101. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas
102. Phase II evaluation of thalidomide in patients with metastatic breast cancer
103. Thalidomide therapy in refractory solid tumour patients
104. Chronic graft-versus-host disease: Is there an alternative to the conventional treatment?
105. Thalidomide for the treatment of chronic graft-versus-host disease
106. Thalidomide treatment for chronic graft-versus-host disease
107. The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children
108. Thalidomide as salvage therapy for chronic graft-versus-host disease
109. Response to thalidomide therapy in refractory chronic graft-versus-host disease
110. Thalidomide in patients with cachexia due to terminal cancer: Preliminary report
111. Effect of thalidomide on gastrointestinal toxic effects of irinotecan
112. Potential novel uses of thalidomide: Focus on palliative care